Trident Texofab Ltd Intrinsic Value
TTFL · Consumer Discretionary · Current price ₹32.3
Is Trident Texofab Ltd undervalued?
DocStoX estimates the fair value of Trident Texofab Ltd at ₹46 per share, versus the current market price of ₹32. That puts the stock about +42.5% below our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹34), Relative P/E (₹74), Graham floor (₹39). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹34 (bear) to ₹46 (base) to ₹74 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹32 versus an intrinsic value of ₹46, Trident Texofab Ltd currently offers +42.5% of margin.
More on Trident Texofab Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.